KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Receivables Refunds (2016 - 2026)

Gsk has reported Receivables Refunds over the past 18 years, most recently at -$411.2 million for Q1 2026.

  • For Q1 2026, Receivables Refunds rose 2.84% year-over-year to -$411.2 million; the TTM value through Mar 2026 reached -$411.2 million, up 2.84%, while the annual FY2025 figure was $383.1 million, 38.96% down from the prior year.
  • Receivables Refunds for Q1 2026 was -$411.2 million at Gsk, down from $383.1 million in the prior quarter.
  • Over five years, Receivables Refunds peaked at $627.6 million in Q4 2024 and troughed at -$981.7 million in Q3 2023.
  • A 5-year average of -$175.2 million and a median of -$321.5 million in 2025 define the central range for Receivables Refunds.
  • Biggest five-year swings in Receivables Refunds: tumbled 167.24% in 2022 and later soared 182.14% in 2025.
  • Year by year, Receivables Refunds stood at $475.0 million in 2022, then decreased by 2.54% to $462.9 million in 2023, then surged by 35.57% to $627.6 million in 2024, then tumbled by 38.96% to $383.1 million in 2025, then tumbled by 207.34% to -$411.2 million in 2026.
  • Business Quant data shows Receivables Refunds for GSK at -$411.2 million in Q1 2026, $383.1 million in Q4 2025, and $495.2 million in Q3 2025.